NCT02166528

Brief Summary

Female pelvic floor dysfunction (FPD) is due to defects in the pelvic support structures, degradation, damage or dysfunction. The main problem of which is pelvic organ prolapse(POP), urinary incontinence(UI) and genital tract injury. Although it does not pose a serious threat to life, but affect the patient's quality of life seriously in the physical, psychological, social behavior and other aspects. With the growing aging population, the incidence rate has gradually increased, and increasing demands for people's quality of life simultaneously, more and more attention was raised to PFD as common chronic diseases. In recent years, the basic research, epidemiology, prevention, diagnosis and treatment of PFD have made great progress, especially in developing gynecological urology theory and reconstructive pelvic surgery. But overall the basic research of PFD is lagging behind, especially susceptibility gene localization and functional studies did not get enough attention.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2013

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2013

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

February 10, 2014

Completed
4 months until next milestone

First Posted

Study publicly available on registry

June 18, 2014

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2016

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2017

Completed
Last Updated

June 18, 2014

Status Verified

June 1, 2014

Enrollment Period

2.9 years

First QC Date

February 10, 2014

Last Update Submit

June 14, 2014

Conditions

Keywords

female pelvic floor dysfunctionpelvic organ prolapsurinary incontinencemassively parallel sequencing

Outcome Measures

Primary Outcomes (1)

  • susceptibility genes localization

    Based on high-throughput sequencing platform, we expect to screen out susceptibility genes location in PFD, providing theoretical basis for individualized prevention, intervention and treatment.

    4 years

Study Arms (2)

experiment group

patients with FPFD

control group

patients without FPFD

Eligibility Criteria

Age30 Years - 70 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The experiment group are patients with PFD. While the control group are volunteer patients without PFD on the basis of informed consent.

You may qualify if:

  • female aging from 30 to 70-year old;
  • preoperative diagnosis of gynecologic malignancies;
  • have the ability to comply with Research programs;
  • voluntarily participate in the study and signed an informed consent form

You may not qualify if:

  • patients with severe cardiovascular diseases, kidney, liver and other vital organs diseases, bone marrow disease and mental illness;
  • patients suffering from autoimmune diseases;
  • patients with acute infectious disease or infection early phase of infection;
  • patients with urinary tract infection;
  • patients with infection or erosion of ano-genital skin;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Obstetrics and Gynaecology, Southwest Hospital, Third Military

Chongqing, Chongqing Municipality, 400038, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

The sample of blood, urine, cervical exfoliated cells and tissue of patients with POP, UI or genital tract injury should be used only in this research with informed consent. The remaining part will be Safekeeping. All information is strictly confidential.

MeSH Terms

Conditions

Urinary Incontinence

Condition Hierarchy (Ancestors)

Urination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director of Obstetrics and Gynecology

Study Record Dates

First Submitted

February 10, 2014

First Posted

June 18, 2014

Study Start

November 1, 2013

Primary Completion

October 1, 2016

Study Completion

October 1, 2017

Last Updated

June 18, 2014

Record last verified: 2014-06

Locations